Firm Known For wrinkle treatment targets rare skin disease.
Have you ever head of this rare skin disease called recessive dystrophic epidermolysis bullosa or RDEB? Below is an Interesting Article about this very rare form of skin disease which is caused by gene mutation which results in the body’s inability to produce fiber, which is usually responsible for holding the skin tissues together.
As a result of this, the skin tissue does not bind together and therfore create skin separations, legions, blisters and wounds at an aggravated scale. The skin becomes very tender which makes it impossible to rob or scratch it without obtaining a wound, scar, or blister.
What makes this article interesting is that the company involved is the research and treatment, has been providing treatment for wrinkles, but it has taking this task of looking for a treatment for this awful rare form of skin disease.
Many company for several years have been treating different kinds of skin disease but very few of them have gone this far into taking a chance to look for a solution for this kind of rare skin disease. As you read this article you will have an appreciation for companies like these that are doing research and development to treat diseases that make life miserable, yet untreatable.
I have seen a lot of different kinds of skin diseases having different effects on individuals but this particular skin disease is at a different level. What makes it worse is that presently, there is no known cure for this disease. It has a similar effect on the body like is yeast infection but the only difference is that yeast infection is usually localized, but RDEB can affect the entire body. Yeast infection also has a cure but this disease does not have any.
By John George Philadelphia Business Journal
A Chester County cell and gene therapy company, initially known for its wrinkle treatment, is advancing its efforts to take on serious skin diseases.
Fibrocell Sciences announced Monday positive preclinical study results for FCX-007, its lead gene therapy drug candidate being developed to treat a rare and inherited condition known as recessive dystrophic epidermolysis bullosa or RDEB.
People with RDEB, which is caused by a gene mutation, lack a key protein responsible for making fibers that hold layers of skin together. The condition results in skin layers separating— which causes severe blistering, open wounds and scarring — in response to any kind of friction, including normal daily activities like rubbing or scratching.
After reading the entire article and knowing how bad this disease is, you will appreciate life especially if neither you non any of your loved ones in suffering from it. We should really appreciate companies like these that are looking for new forms of treatment geared towards diseases that are presently non treatable.